Five Prime Therapeutics

Latest Headlines

Latest Headlines

GlaxoSmithKline and Five Prime ditch lung cancer ambitions as rivals pile in

Partners GlaxoSmithKline and Five Prime Therapeutics are abandoning their hopes of developing an early-stage drug for lung cancer, pivoting to mesothelioma as the landscape gets more and more competitive.

Bristol-Myers inks a blockbuster $1.74B deal for an Opdivo combo drug

Bristol-Myers Squibb has struck a $1.74 billion deal--fronted with a $350 million cash buy-in--to grab worldwide rights to an early-stage anti-immunosuppression drug from Five Prime that can be combined with its pioneering checkpoint inhibitor Opdivo.

Five Prime bets up to $452.5M on Inhibrx's cancer antibodies

Five Prime Therapeutics is buying to Inhibrx's early-stage cancer R&D, signing a deal worth up to $452.5 million to get its hands on an immuno-oncology project.

Bluebird widens its CAR-T ambitions with a $130M Five Prime deal

Bluebird bio, already making headlines with its promising gene therapy, is expanding its efforts in immuno-oncology, pairing up with Five Prime Therapeutics to develop cell therapies for cancer.

Five Prime hitches onto Bristol-Myers' blockbuster-in-waiting immunotherapy

Bristol-Myers Squibb has signed a deal with Five Prime Therapeutics to determine whether a combination of its star immuno-oncology contender and the biotech's antibody can make a difference in a range of cancers.

GlaxoSmithKline cozies up to Five Prime for respiratory R&D

GlaxoSmithKline, facing widespread scrutiny for its underperforming respiratory business, has expanded its relationship with Five Prime Therapeutics, digging in to discover new treatments in the field.

Bristol-Myers inks a $650M deal to pair with Five Prime on immuno-oncology gold rush

Bristol-Myers Squibb, a leader in the race to develop new immuno-oncology therapies, is pairing up with Five Prime Therapeutics to come up with a second set of cancer therapies that target two undisclosed immune checkpoint pathways in a deal worth up to $350 million.

Langer's Bind, Acceleron and Five Prime set terms for next batch of biotech IPOs

Three well-groomed biotech outfits aim to sustain the frenzy for new biotech stocks on Wall Street. This week Acceleron Pharma, Bind Therapeutics and Five Prime Therapeutics proposed price ranges for their planned initial public offerings.

Five Prime Therapeutics pitches $60M IPO after string of pharma collaborations

Five Prime Therapeutics wants to follow more than two dozen other drug developers this year onto the public market. The South San Francisco-based biotech, a developer of protein drugs, has filed paperwork to complete an initial public offering.

FivePrime scores $495M cancer deal with Human Genome Sciences

Fresh off the approval of lupus drug Benlysta, red-hot Human Genome Sciences ($HGSI) is paying $50 million up front and up to $445 million in milestones to gain development rights for FivePrime's